参考文献/References:
[1]赖全友,高远,王尚毓,等.MRI联合血清赖氨酸氧化酶样蛋白4、信号转导和转录激活因子3检测用于原发性肝癌诊断的价值[J].陕西医学杂志,2024,53(10):1398-1401,1406.
[2]曹虹丽,彭廷云,陈青山,等.柴芍六君子汤对原发性肝癌患者化疗期间疗效及免疫功能的影响[J].陕西中医,2024,45(11):1495-1498.
[3]汪慧,胡亮,邹珊珊,等.C型凝集素结构域家族1成员B在肝细胞癌中的表达及临床意义[J].第二军医大学学报,2019,40(5):547-553.
[4]AGIN A,KIRATLI H,GURESCI S,et al.Evaluation of HSP-27,BAP1,BRAF V600E,CCR7,and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors[J].Int J Biol Markers,2022,37(2):200-209.
[5]SALEM A,ALOTAIBI M,MROUEH R,et al.CCR7 as a therapeutic target in cancer[J].Biochim Biophys Acta Rev Cancer,2021,1875(1):188499.
[6]章方莉,赵欢,刘珊.肺鳞状细胞癌组织PCBP1、GPSM2表达与EMT、临床病理特征和预后的关系[J].分子诊断与治疗杂志,2024,16(7):1229-1233.
[7]DENG M,LIU B,ZHANG Z,et al.Knockdown of G-protein-signaling modulator 2 promotes metastasis of non-small-cell lung cancer by inducing the expression of Snail[J].Cancer Sci,2020,111(9):3210-3221.
[8]中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志,2015,31(6):833-839.
[9]廖宇圣,张姮,李晖,等.CCR7在人肝癌组织中的表达及其与临床病理特征的关系[J].华中科技大学学报(医学版),2017,46(6):669-672.
[10]代云龙,黄纪伟.CLEC1B、DKK1、DRD4在原发性肝癌病变组织中的表达及临床意义探究[J].医学分子生物学杂志,2024,21(3):224-230.
[11]霍亮,骆杨,冯海林.肝癌组织中GPSM2、TGF-β1蛋白表达水平及临床意义[J].实用癌症杂志,2024,39(3):406-410.
[12]CHOWDHURY M M H,SALAZAR C J J,NURUNNABI M.Recent advances in bionanomaterials for liver cancer diagnosis and treatment[J].Biomater Sci,2021,9(14):4821-4842.
[13]胡薪蕊,吴熙,殷玉琨,等.α-干扰素联合索拉菲尼对肝癌细胞增殖的抑制作用及其对STAT3通路的影响[J].陕西医学杂志,2024,53(10):1309-1313.
[14]管宇帆,甘雨,安家泽.青年肝癌发病特征及危险因素的思考[J].空军军医大学学报,2024,45(1):101-105.
[15]卿小松,王学文,罗国松,等.载药微球联合TACE治疗原发性肝癌患者的效果观察[J].临床误诊误治,2024,37(12):26-30.
[16]冯洁,蔡勋全,潘勤聪.趋化因子及其受体在肝癌中的功能及预后价值[J].肝脏,2024,29(3):293-299.
[17]陈媛,李昀晖,梁静,等.肿瘤微环境相关基因CCR7在肝癌铜死亡中的作用及其作为肝癌预后标志物的探索性研究[J].中华检验医学杂志,2024,47(10):1169-1177.
[18]刘林弟,吕庆杰.GPSM2在肿瘤中作用机制的研究进展[J].基础医学与临床,2024,44(10):1447-1450.
[19]刘鹏,李永宁,潘耀振.G蛋白信号调节蛋白2在肝癌组织中的表达及临床意义[J].贵州医药,2018,42(2):157-159.
[20]郭勇,莫缓椰,鲁叶,等.G蛋白信号调节蛋白2在肝癌组织中的表达及其对细胞增殖和糖酵解的影响[J].中国普通外科杂志,2021,30(1):55-63.
[21]HU K,WANG Z M,LI J N,et al.CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage[J].Transl Oncol,2018,11(2):552-558.
[22]ZHANG G,SU L,LV X,et al.A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma[J].Cancer Cell Int,2021,21(1):522.
[23]郑焱焱,林一均,缪一艇,等.CCR7在肿瘤中的研究应用进展[J].浙江医学,2019,41(4):397-400.
[24]孙正路,王航宇,张艳停.CCR7、FAM96A蛋白在肝癌组织中的表达及临床意义[J].实用癌症杂志,2023,38(9):1410-1413.
[25]FENG J,LI J,WU L,et al.Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J].J Exp Clin Cancer Res,2020,39(1):126.
[26]沈利,李红霞.趋化因子受体CCR7蛋白在肝细胞癌组织中的表达及临床意义[J].肝脏,2018,23(1):56-59.
[27]易华,袁宏伟,孙勤暖,等.肝细胞肝癌组织GPSM2、GFPT2、SNORA51 mRNA表达与临床病理特征的关系及对预后的影响研究[J].现代生物医学进展,2023,23(4):733-738,791.
相似文献/References:
[1]郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析*[J].陕西医学杂志,2019,(7):850.
[2]李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,(7):873.
LI Xun,ZHANG Xianglin..Efficacy observation and TSGF change in primary hepatocellular carcinoma by TACE and entecavir[J].,2019,(9):873.
[3]陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
TAO Lin.Application of antibiotics and risk factors of secondary infection in patients with primary liver cancer after chemotherapy[J].,2023,52(9):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
[4]刘立友,吴东洋,蔡青山,等.原发性肝癌组织中层粘连蛋白3、黏着斑激酶蛋白表达及其与患者临床病理特征和预后关系研究[J].陕西医学杂志,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
LIU Liyou,WU Dongyang,CAI Qingshan,et al.Expression of LAMA3 and FAK proteins in primary liver cancer and their relationship with clinicopathological features and prognosis of patients[J].,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
[5]刘贤国,徐红玉,朱 江.原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展[J].陕西医学杂志,2023,52(10):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
LIU Xianguo,XU Hongyu,ZHU Jiang.Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols[J].,2023,52(9):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
[6]李晓勤,王 群,何晓兰,等.多模式镇痛对原发性肝癌患者休斯顿疼痛情况调查表评分及血清结合珠蛋白水平的影响[J].陕西医学杂志,2024,(4):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
LI Xiaoqin,WANG Qun,HE Xiaolan,et al.InfLuences of multimodal analgesia on HPOI score and serum haptoglobin level in patients with hepatocellular carcinoma[J].,2024,(9):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
[7]孟凡岗,刘文宇,甄立军,等.原发性肝癌组织长链非编码RNA JPX、微小RNA-371a-5p表达水平及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,(8):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
MENG Fangang,LIU Wenyu,ZHEN Lijun,et al.Expression levels of long non-coding RNA JPX and microRNA-371a-5p in primary liver cancer tissues and their relationship with 5-year prognosis of patients after surgery[J].,2024,(9):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
[8]万仁均,罗文强,刘鑫.血清HSP90α、GPC3、AFP-L3水平对早期原发性肝细胞癌的诊断价值[J].陕西医学杂志,2025,54(9):1248.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.017]
WAN Renjun,LUO Wenqiang,LIU Xin.Diagnostic value of serum HSP90α,GPC3,and AFP-L3 levels in early primary hepatocellular carcinoma[J].,2025,54(9):1248.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.017]